Highlights of weekly biotech stock moves

Mela Sciences Inc. (NASDAQ:MELA) rose $1.26 (56%) to $3.50 on Wednesday after receiving CE Mark approval in the EU for MelaFind to aid in the detection of melanoma. The company plans to launch the diagnostic in Germany in 4Q11. A PMA for MelaFind is under FDA review. Mela was up $1.08 (50%) to $3.24 last week.

4SC AG (Xetra:VSC) gained €0.19 (12%) to €1.78 last week after resminostat met the primary endpoint of overall response rate in the Phase II SAPHIRE trial to treat relapsed or refractory Hodgkin's lymphoma (see B15)...